NYT v. FDA's Gottlieb On Drug Approval Standards
Executive Summary
New York Times editorial is critical of approving drugs based on one clinical trial, recommends independent cost benefit analysis.
You may also be interested in...
Gottlieb Uses ASCO Platform To Unveil Two Pilot Programs To Speed Drug Review
US FDA commissioner outlines plans to allow partial submissions as soon as database locks and to create joint sponsor-agency review documents.
FTC Set To Take Enforcement Action Against Drugmakers Over Orange Book Patent Listings
Merger reviews could take into account sponsor's Orange Book behavior. FTC's statement does not detail what would make a patent listing 'improper' but the precedents from court cases against various sponsors should offer industry some guideposts.
Real-World Data Or Studies Of Competitor Drugs Can Serve As Confirmatory Evidence For US FDA
Draft guidance describes seven types of confirmatory evidence that can be used with one adequate and well-controlled clinical study to demonstrate substantial evidence of effectiveness, including evidence from expanded access, real-world data, and studies of other drugs in the same class.